Related Experiment Videos
Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing
M C Smith1, C D Pendleton, V E Maher
1Molecular Immunogenetics and Vaccine Research Section, National Cancer Institute, National Institutes of Health, Bethesda MD 20892-1578, USA.
International Immunology
|August 1, 1997
Summary
Mutant ras proteins can be targeted by cancer vaccines. This study shows how ras mutations affect antigen processing and presentation, crucial for designing effective ras-specific tumor immunity vaccines.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Point mutations in oncogenes like ras can create tumor antigens.
- These neoantigens can be recognized by T lymphocytes, forming the basis for cancer vaccines.
- Effective cancer vaccines require proper antigen processing and presentation by HLA molecules.
Purpose of the Study:
- To investigate how ras codon 12 and 13 point mutations affect antigen processing and binding to HLA-A2.1.
- To understand the impact of these mutations on the generation of tumor antigens for T cell recognition.
Main Methods:
- Analysis of ras point mutations and their predicted binding to HLA-A2.1.
- Investigation of extracellular antigen processing, including trimming of flanking residues and susceptibility to proteolysis.
Main Results:
- Different ras mutations impact binding affinity to HLA-A2.1.
- Mutations influence extracellular antigen processing, affecting both residue trimming and the stability of antigenic peptides.
- Internal residues affect cleavage of flanking residues, indicating complex interactions in antigen processing.
Conclusions:
- Ras mutations significantly influence antigen processing and presentation.
- Understanding these effects is critical for designing effective vaccines targeting mutant ras-specific tumor immunity.
- These findings have implications for developing novel cancer immunotherapies.